Molecular determinants of the cardiometabolic phenotype

Lisa de las Fuentes, Giovanni de Simone, Donna K. Arnett, Víctor G. Dávila-Román

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The metabolic syndrome represents a clustering of risk factors that has been shown to predict adverse cardiovascular outcomes. Although the precise mechanisms contributing to the cardiometabolic syndrome (CMS) remain poorly defined, accumulating evidence identifies two intersecting candidate pathways responsible for inflammation and energy homeostasis in the pathophysiology that underlie cardiometabolic traits. Although currently no pharmacologic interventions specifically target CMS, future drug development efforts should attempt to capitalize on molecular nodes at the intersections of these pathways in the CMS.

Original languageEnglish
Pages (from-to)109-123
Number of pages15
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
Issue number2
StatePublished - 2010


  • Cardiometabolic syndrome
  • Dyslipidemia
  • Hypertension
  • Inflammation
  • Insulin resistance
  • Metabolic syndrome
  • Obesity
  • Substrate metabolism


Dive into the research topics of 'Molecular determinants of the cardiometabolic phenotype'. Together they form a unique fingerprint.

Cite this